Cancel

Integrating Therapeutic Advances to Improve Current Practices in Myeloma Patient Care

Improving outcomes for patients with multiple myeloma requires building on the foundation of current therapies with new agents and combinations, recognizing the nature of each individual patient’s disease, and providing a personalized approach to treatment. This activity uses evidence-based presentations and case study vignettes to present the latest information on selecting the most appropriate therapy based on patient profile, clinical evidence, and assessment of risk-versus-benefit. Le...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

Navigating New Options to Improve Outcomes in Multiple Myeloma

As new combinations and classes of agents emerge for the treatment of multiple myeloma (MM), community-based treatment teams require clarity on the optimal integration of recently approved and emerging agents into the relapsed/refractory landscape for MM. While high-dose chemotherapy is not appropriate for all patients, multiple options have emerged that demonstrate a clinical benefit and require proper integration into the treatment paradigm. In addition, clinicians must meet requirements for...
The Potomac Center for Medical Education, Postgraduate Institute for Medicine, and Rockpointe Oncology.

4th Annual Ash 2018 Updates: Practice Changing Abstracts

Patients in medically underserved communities have limited access to subspecialty care. Community-based oncologists are well positioned to provide initial care for these patients, but often do not have the knowledge and confidence to manage difficult cases. According to the 2015 Community Health Needs Assessment, between 2006 and 2008, the City of Chicago experienced an annual average adjusted cancer mortality rate of 194.2 deaths per 100,000 individuals. Cancer mortality has decreased over th...
Meeting Achievement

New Drugs Approved in 2015

In 2015, the FDA’s Center for Drug Evaluation and Research (CDER) approved 45 new molecular entities – the highest annual number of new drugs to be approved in the past decade (up from 41 in 2014). The new approvals include 16 first-in-class drugs spanning 14 different medical conditions. Many of the new drugs were approved under one or more of the FDA’s 4 expedited pathways (fast track, breakthrough, priority review, and accelerated approval). Nearly half are for the treatment of rare d...
The Rx Consultant

The Brigham Board Review in Hematology and Oncology

Get ready for the ABIM exam in Hematology-Oncology by studying this Brigham Board Review in Hematology and Oncology. Topics covered by the Brigham Board Review in Hematology and Oncology include: Molecular Genetics of Cancer, Cancer Drug Development, Hematopoietic Stem Cell Transplantation, Acute Leukemias, Myelodysplastic Syndrome, Multiple Myeloma, Hodgkin's Lymphoma, B Cell Malignancies, Mesothelioma, Thyroid Cancer and dozens of others. After completing the Brigham Board Review in Hemat...
CMEInfo

The Evolution of Multiple Myeloma Patient Management: Managing Today, Preparing for Tomorrow

The clinical multiple myeloma arena has undergone significant advances in diagnosis and prognosis, minimal residual disease monitoring, and supportive care. This expansion brings renewed hope to patients, but it presents new challenges for the clinicians charged with their care. Some patients enjoy many years in clinical remission, whereas for others survival is no more than 2 or 3 years. This reflects the heterogeneity of myeloma and underscores the inappropriateness of a one-size-fits-all ma...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

Nursing Management of Bone Health in Patients With Cancer

STATEMENT OF NEED Many tumors, such as prostate, breast, lung, and multiple myeloma, affect bone health. Once cancer spreads to the skeletal system, the risk for pain, fractures, hypercalcemia, and nerve compression increases considerably. Several studies have shown that the use of antiresorptive agents such as bisphosphonates and monoclonal antibodies can reduce the morbidity of skeletal complications in patients with cancer and significantly improve quality of life. Combined with preventi...
i3 Health

Osler Radiation Oncology Online Review

The Osler Institute utilized state of the art equipment to record the comprehensive Radiation Oncology Review Course and bring it to you! These audio files are stored “in the cloud” so you can stream them anywhere, anytime, as long as you have an internet connection – your learning experience is almost like being at the live activity, but without travel costs and time away from your practice. The Osler Radiation Oncology Review also offers a variety of live Radiation Oncology board revie...
Osler Institute

Osler Surgery MOC Online Review

The Osler Institute utilized state of the art equipment to record the comprehensive Radiation Oncology Review Course and bring it to you! These audio files are stored “in the cloud” so you can stream them anywhere, anytime, as long as you have an internet connection – your learning experience is almost like being at the live activity, but without travel costs and time away from your practice. The Osler Radiation Oncology Review also offers a variety of live Radiation Oncology board revie...
Osler Institute

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.